Sanofi-aventis and US Biopharmaceutical Company Ascenta Therapeutics Sign License Agreement in Oncology
Small molecules could restore Tumor Cell Apoptosis by reactivating tumor suppressor functions of the p53 gene
08-Jun-2010 -
Sanofi-aventis and Ascenta Therapeutics announced the signature of an exclusive global collaboration and licensing agreement on a number of compounds that could restore tumor cell apoptosis. These compounds inhibit the p53-HDM2 (Human Double Minute 2) protein-protein interaction, leading ...
inhibitors
milestone payments
oncology
+3